Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Operating Grant

University of Toronto

$263,673.00

Constitutive Smooth Muscle Tumor Necrosis Factor Regulates Microvascular Myogenic Responsiveness and Systemic Blood Pressure

EF 2013-14

Résumé
Tumor necrosis factor (TNF) is a highly-researched disease mediator that is known to alter blood vessel function. This proposal advances the novel concept that TNF is, in fact, a regulator of blood vessel function in healthy individuals. This new concept drives a significant implication: the clinical use of anti-TNF therapy may unexpectedly lower blood pressure or increase the demands on the heart. Such effects could explain why anti-TNF therapy failed in clinical trials for use in heart failure patients. This proposal has three primary goals: (1) to assess the effects of anti-TNF therapy on critical cardiovascular parameters (e.g., blood pressure) and (2) to understand the molecular mechanisms that TNF utilizes and (3) to translate this knowledge to human blood vessels and experimental models used for clinical trials.
Programme
Operating Grant
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
304953
Name
Bolz Steffen S
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Cardiovascular System - C: Vascular System
Projecttitle
Constitutive Smooth Muscle Tumor Necrosis Factor Regulates Microvascular Myogenic Responsiveness and Systemic Blood Pressure
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$263,673
Cihrequipment2
$0
Programname2
Operating Grant
Keyworddelim
Conditional Knockout; Etanercept; Human Vessels; Infliximab; Myogenic Tone; Signal Transduction; Tumour Necrosis Factor
Abstract
Tumor necrosis factor (TNF) is a highly-researched disease mediator that is known to alter blood vessel function. This proposal advances the novel concept that TNF is, in fact, a regulator of blood vessel function in healthy individuals. This new concept drives a significant implication: the clinical use of anti-TNF therapy may unexpectedly lower blood pressure or increase the demands on the heart. Such effects could explain why anti-TNF therapy failed in clinical trials for use in heart failure patients. This proposal has three primary goals: (1) to assess the effects of anti-TNF therapy on critical cardiovascular parameters (e.g., blood pressure) and (2) to understand the molecular mechanisms that TNF utilizes and (3) to translate this knowledge to human blood vessels and experimental models used for clinical trials.
Competitiondate
201403
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Bolz, Steffen S
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $263,673~ $0~